Current Liabilities decreased faster than Novo Nordisk A's Cash & cash equivalent, this led to improvement in Novo Nordisk A's Quick Ratio to 1.43, Quick Ratio remained below Novo Nordisk A average.

Within Major Pharmaceutical Preparations industry 373 other companies have achieved higher Quick Ratio than Novo Nordisk A in first quarter 2026. While Quick Ratio total ranking has improved so far during the Q1 2026 to 2009, from total ranking in the fourth quarter 2025 at 4590.

Explain Quick Ratio?
How much Cash & cash equivalents NVO�s has?
What are NVO�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/NVO/financial-strength

https://api.csimarket.com/api/v1/companies/NVO/fundamentals

https://api.csimarket.com/api/v1/companies/NVO/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

NVO Quick Ratio	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2	0 Q1
Y / Y Current Liabilities Change	-93.27 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	-33.8 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	1.43	Subscribe	Subscribe	Subscribe	Subscribe
NVO's Total Ranking	# 2009	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	-88.94 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-33.8 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio first quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 374
Healthcare Sector	# 667
Overall Market	# 2009

Quick Ratio Statistics
High	Average	Low
12.96	1.87	0
(Dec 31 2025)		(Dec 31 2024)

Financial Statements
Novo Nordisk A's Current Liabilities	$ 2,282 Millions	Visit NVO's Balance sheet
Novo Nordisk A's Cash & cash equivalent	$ 3,257 Millions	Visit NVO's Balance sheet
Source of NVO's Sales		Visit NVO's Sales by Geography

Cumulative Novo Nordisk A's Quick Ratio

NVO's Quick Ratio for the trailling 12 Months

NVO Quick Ratio	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months	0 12 Months
Y / Y Current Liabilities TTM Growth	-51.05 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	-31.65 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	0.52	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 3792	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	-50.38 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	-9.35 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to NVO Financial Strength Comparisons >> Go to Compare NVO Quick Ratio to its Competitors

On the trailing twelve months basis Current Liabilities decreased faster than Novo Nordisk A's average Cash & cash equivalent, this led to increase in in Novo Nordisk A's Quick Ratio to 0.52, above NVO average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 523 other companies have achieved higher Quick Ratio than Novo Nordisk A. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2025 from 4191 to 4384.

Explain Quick Ratio?
How much Cash & cash equivalents NVO�s has?
What are NVO�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 524
Healthcare Sector	# 1060
Within the Market	#

trailing twelve months Quick Ratio Statistics
High	Average	Low
0.29	0.15	0.07
(Dec 31 2018)		(Dec 31 2024)

Companies with similar Quick Ratio in the quarter ending Mar 31 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Mar 31 2026 MRQ Cash & cash equivalent	Mar 31 2026 MRQ Current Liabilities
Maravai Lifesciences Holdings Inc	3.89	$ 165.922 Millions	$ 42.622 Millions
Serina Therapeutics Inc	3.87	$ 24.526 Millions	$ 6.340 Millions
Aclaris Therapeutics Inc	3.85	$ 105.416 Millions	$ 27.370 Millions
Genelux Corporation	3.77	$ 26.209 Millions	$ 6.956 Millions
Scynexis Inc	3.73	$ 59.263 Millions	$ 15.900 Millions
Gt Biopharma Inc	3.69	$ 8.923 Millions	$ 2.416 Millions
Pulmatrix Inc	3.67	$ 3.324 Millions	$ 0.905 Millions
Acurx Pharmaceuticals inc	3.66	$ 9.255 Millions	$ 2.527 Millions
Longeveron Inc	3.63	$ 15.758 Millions	$ 4.345 Millions
Reviva Pharmaceuticals Holdings Inc	3.63	$ 22.190 Millions	$ 6.119 Millions
Xilio Therapeutics Inc	3.62	$ 150.333 Millions	$ 41.576 Millions
United Therapeutics Corporation	3.59	$ 2,153.700 Millions	$ 599.100 Millions
Arbutus Biopharma Corp	3.55	$ 23.719 Millions	$ 6.676 Millions
Vistagen Therapeutics Inc	3.55	$ 45.403 Millions	$ 12.795 Millions
Hepion Pharmaceuticals Inc	3.54	$ 2.603 Millions	$ 0.736 Millions
Enanta Pharmaceuticals Inc	3.53	$ 163.774 Millions	$ 46.442 Millions
Rani Therapeutics Holdings Inc	3.50	$ 43.403 Millions	$ 12.395 Millions
Aquestive Therapeutics Inc	3.49	$ 110.734 Millions	$ 31.753 Millions
Calcimedica Inc	3.48	$ 8.164 Millions	$ 2.347 Millions
Inhibitor Therapeutics Inc	3.38	$ 1.291 Millions	$ 0.382 Millions
Rhythm Pharmaceuticals Inc	3.32	$ 340.625 Millions	$ 102.522 Millions
Tao Synergies Inc	3.30	$ 3.646 Millions	$ 1.104 Millions
Bolt Biotherapeutics Inc	3.12	$ 22.892 Millions	$ 7.343 Millions
Kyntra Bio Inc	3.10	$ 87.237 Millions	$ 28.114 Millions
Compass Pathways Plc	3.07	$ 466.389 Millions	$ 151.904 Millions
Aptevo Therapeutics Inc	3.05	$ 14.525 Millions	$ 4.760 Millions
Polaryx Therapeutics Inc	3.04	$ 3.080 Millions	$ 1.014 Millions
Nanoviricides inc	3.02	$ 3.213 Millions	$ 1.065 Millions
Kiniksa Pharmaceuticals International Plc	2.99	$ 468.093 Millions	$ 156.611 Millions
Harmony Biosciences Holdings inc	2.95	$ 640.918 Millions	$ 217.340 Millions

Date modified: 2026-10-15T05:23:38+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.